Latest Conference Articles

Posters reported the prevalence of autoimmune comorbidities among patients with vitiligo, demonstrating the need for earlier screenings and updated clinical guidelines.

Based on the findings, investigators acknowledged the critical need to consider racial differences when assessing patients with hidradenitis suppurativa. Health care providers should be vigilant in addressing cardiovascular risk factors in this population, recognizing and addressing racial disparities that may impact disease management.

Posters presented showed that patients with vitiligo have a heightened risk of stigma and subsequent mental health issues.

Posters presented at the American Academy of Dermatology Annual Meeting demonstrated both short- and long-term efficacy and safety profiles of brodalumab in patients with moderate to severe psoriasis.

Shawn Kwatra, MD, dermatologist, John Hopkins University, discusses late breaking study results on the long-term efficacy and safety of nemolizumab in patients with prurigo nodularis (PN).

Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh, shares 16-week safety and efficacy data from the FRONTIER 2 clinical trial on JNJ-2113 for patients with moderate to severe plaque psoriasis.

Krystyn Van Vliet, PhD, vice president for research and innovation at Cornell University's Meinig School of Biomedical Engineering, discusses using engineered 3D platforms to identify potential multiple sclerosis (MS) drug candidates.

Research presented at the American Academy of Dermatology Annual Meeting 2024 explored the impact of social determinants of health on hidradenitis suppurativa severity.

AnaptysBio's senior vice president of research, Martin Dahl, PhD, discusses therapeutic strategies and pathophysiological approaches to treating patients with atopic dermatitis (AD).

Experts at the American Academy of Dermatology Annual Meeting shared results of research into various topical and systemic therapies for atopic dermatitis (AD) and hidradenitis suppurativa during a late-breaking abstract session.

Presented posters showed that moderate to severe atopic dermatitis (AD) in skin of color can be treated with either biologic or topical therapies.

In patients with moderate to severe atopic dermatitis, nemolizumab demonstrated good durability of response, explained Jonathan Silverberg, MD, PhD, MPH, FAAD, of George Washington University School of Medicine and Health Sciences.

Treating pediatric and adult patients with hidradenitis suppurativa (HS) who are in socioeconomically underserved areas can be done through collaboration with the patient, their family, and other clinicians in the field.

Pictures of darker skin with vitiligo make up more than three-quarters of Google searches for pictures of vitiligo, according to posters.

Monica Li, MD, medical and cosmetic dermatologist and clinical assistant professor, University of British Columbia, discusses how microneedling can address both aesthetic and medical dermatological needs across different skin types.

Robert Sidbury, MD, MPH, FAAD, division head of dermatology at Seattle Children's Hospital and professor of pediatrics at the University of Washington School of Medicine, discusses what makes a dermatology practice successful and the challenges that come with running a practice.

A session held at the American Academy of Dermatology Annual Meeting 2024 highlighted the ways in which atopic dermatitis can be treated and addressed in adults and older adults.

There are key factors to consider when selecting which patients with atopic dermatitis (AD) are suitable candidates for oral Janus kinase (JAK) inhibitors, explained Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology and Immunology Research.

A physician-reported outcomes survey found that physicians switched to ruxolitinib cream due to lack of effectiveness with previous atopic dermatitis (AD) treatments, and an analysis of claims data revealed the cream reduced the need for other treatments.

Amy S. Paller, MD, chair of dermatology, Feinberg School of Medicine at Northwestern University, discusses aspects of this year's American Academy of Dermatology (AAD) conference she is most excited about.

The American Academy of Dermatology (AAD) will host its annual conference in San Diego from March 8 to March 11, 2024, which will include sessions about Janus kinase (JAK) inhibitors, biologics, and other treatments for skin disorders.

While the results of evolutionRMS, comparing evobrutinib with teriflunomide, were negative, that "doesn't mean that evobrutinib is not working," said Xavier Montalban, MD, PhD, director of the Multiple Sclerosis Center of Catalonia (Cemcat).

Ateyeh Soroush, a PhD candidate at the University of Calgary, explains her ongoing study utilizing near-infrared spectroscopy (NIRS) to investigate hypoxia-related brain function impairment in patients with multiple sclerosis (MS).

The poster session at the Americas Committee for Research and Treatment in Multiple Sclerosis (ACTRIMS) Forum 2024 dedicated a section to emerging developments in the use of artificial intelligence (AI) in research and treatment approaches in multiple sclerosis (MS).

Speakers on the final day of the Americas Committee for Research and Treatment in Multiple Sclerosis (ACTRIMS) Forum 2024 discussed advancements in rehabilitation trials in multiple sclerosis (MS) and unmet research needs.

Kathy Zackowski, PhD, associate vice president of the National Multiple Sclerosis (MS) Society, discusses the importance of MS rehabilitation and lists several successful strategies.

On day 2 of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024, speakers gave great attention to novel developments in the field of imaging and 3D modeling in multiple sclerosis (MS).

Ari Green, MD, of the University of California, San Francisco, details the benefits of remyelination for patients with multiple sclerosis (MS), as well as the challenges faced when conducting remyelination trials.